<SEC-DOCUMENT>0000899243-23-008999.txt : 20230317
<SEC-HEADER>0000899243-23-008999.hdr.sgml : 20230317
<ACCEPTANCE-DATETIME>20230317203012
ACCESSION NUMBER:		0000899243-23-008999
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20230315
FILED AS OF DATE:		20230317
DATE AS OF CHANGE:		20230317

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Deniger Drew
		CENTRAL INDEX KEY:			0001921961

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33038
		FILM NUMBER:		23744658

	MAIL ADDRESS:	
		STREET 1:		C/O ALAUNOS THERAPEUTICS, INC.
		STREET 2:		8030 EL RIO ST.
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77054

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alaunos Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001107421
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				841475642
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		8030 EL RIO STREET
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77054
		BUSINESS PHONE:		(346) 355-4099

	MAIL ADDRESS:	
		STREET 1:		8030 EL RIO STREET
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77054

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZIOPHARM ONCOLOGY INC
		DATE OF NAME CHANGE:	20050919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EASYWEB INC
		DATE OF NAME CHANGE:	20010213
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc4.xml
<DESCRIPTION>FORM 4 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2023-03-15</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001107421</issuerCik>
        <issuerName>Alaunos Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>TCRT</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001921961</rptOwnerCik>
            <rptOwnerName>Deniger Drew</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ALAUNOS THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>8030 EL RIO ST.</rptOwnerStreet2>
            <rptOwnerCity>HOUSTON</rptOwnerCity>
            <rptOwnerState>TX</rptOwnerState>
            <rptOwnerZipCode>77054</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>See Remarks</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Employee Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>0.50</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2023-03-15</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>125000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2033-03-14</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>125000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>125000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">One-sixteenth of the shares underlying the option vest in equal quarterly installments measured from March 15, 2023, with the first vesting occuring on June 15, 2023, subject to the Reporting Person's continued service through each such date.</footnote>
    </footnotes>

    <remarks>Vice President, Research and Development</remarks>

    <ownerSignature>
        <signatureName>/s/ Melinda Lackey, Attorney-in-Fact</signatureName>
        <signatureDate>2023-03-17</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
